

The Manager
Company Announcements Office
ASX Limited

LBT RECEIVES \$3M 2014 R&D TAX INCENTIVE

4 September 2014, Adelaide: LBT Innovations Limited (ASX:LBT) has received its Australian R&D tax incentive cash of \$3,014,158 following its FY2014 tax return. The incentive refund amount is greater than the \$2.7 million estimated to the market in May 2014.

This cash injection combined with a \$1 million joint venture milestone payment received in June, \$1.5 million raised in a placement in June and just over \$500k from a shareholder purchase plan in July all support the trial and ramp up stage of the company's second flagship product the automated plate assessment system (APAS).

"This non-dilutive funding is a tremendous support for innovative companies commercialising new products for worldwide markets," said LBT CEO Lusia Guthrie.

"The funding not only supports bringing our APAS product to market but allows us to focus deeper into the pipeline to our Woundvue product development. LBT has a track record of successful product delivery and our intent is to enlarge this success for the betterment of shareholders and the country as a whole."

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has 2 breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™ a proposed automation solution to assist in the management of chronic wounds.

LBT has a global, exclusive licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in around the world. LBT's APAS® technology (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au